Abstract 104P
Background
Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. Cadonilimab (AK104) is a bispecific antibody targeting PD-1 and CTLA-4 simultaneously. Here, we reported the efficacy and safety of cadonilimab with or without single-agent chemotherapy as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy.
Methods
The study population derived from retrospectively analyzed data (08/2022-04/2024) of patients treated with cadonilimab as second- or later-line therapy for metastatic NSCLC at Affiliated Hospital of Guangdong Medical University. Baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were analyzed.
Results
21 patients were enrolled, of which 11 (52.3%) received cadonilimab as a third or later line therapy. The median age was 66 years old (range: 54-87), 16 (76.2%) were male, 10 (47.6%) had ECOG PS 2 or 3, and 4 (19.0%) had brain metastasis. Among evaluable patients, 5 reached partial response (PR) and 9 were stable disease (SD). The ORR was 29.4% and DCR was 82.4%. The median PFS was 6.77 months (95% confidence interval: 5.28-8.27) and median OS was not mature. Three patients (14.3%) experienced grade≥3 TRAEs. The most common TRAEs (≥10%) included anemia (42.9%), hypoleukocytosis (28.6%), and aspartate aminotransferase increased (19.1%), hypothyroidism(14.3%), alanine aminotransferase increased(14.3%). No treatment-related deaths were reported.
Conclusions
This real-world analysis further confirmed the promising efficacy and safety of cadonilimab as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy. Further exploration is ongoing and the updated analysis in a larger population is expected in the future.
Legal entity responsible for the study
Hualin Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract